IOP-Lowering Efficacy of Bimatoprost 0.03% and Travoprost 0.004% in Patients with Glaucoma or Ocular Hypertension

BACKGROUND/AIMS: To evaluate the IOP-lowering efficacy of bimatoprost and travoprost for the treatment of glaucoma and ocular hypertension. METHODS: Prospective, randomized, investigator- masked, parallel-group clinical trial. After completing a washout from any glaucoma medications, patients (n=157) were randomized to bimatoprost or travoprost for 6 months. Visits were at baseline, week 1, and months 1, 3, and 6. IOP was measured at 9 AM at each visit and also at 1 and 4 PM at baseline and months 3 and 6. RESULTS: There were no significant between-group differences in baseline IOP at 9AM, 1PM, or 4PM (P>.741). After 6 months, both medications significantly reduced IOP at every time point (P<.001). After 6 months, mean IOP reduction at 9AM was 7.1 mm Hg (27.9%) with bimatoprost (n=76) and 5.7 mm Hg (23.3%) with travoprost (n=81) (P=.014). At 1PM, mean IOP reduction was 5.9 mm Hg with bimatoprost (25.3%) and 5.2 mm Hg (22.4%) with travoprost (P=.213). At 4 PM, the mean IOP reduction was 5.3 mm Hg (22.5%) with bimatoprost and 4.5 mm Hg (18.9%, P=.207) with travoprost. Both study medications were well tolerated, with ocular redness the most commonly reported adverse event in both treatment groups. CONCLUSIONS: Bimatoprost provided greater mean IOP reductions than travoprost.